Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

KalVista Pharmaceuticals (KALV) Operating Expenses: 2013-2025

Historic Operating Expenses for KalVista Pharmaceuticals (KALV) over the last 13 years, with Apr 2025 value amounting to $188.0 million.

  • KalVista Pharmaceuticals' Operating Expenses fell 5.46% to $45.8 million in Q2 2025 from the same period last year, while for Apr 2025 it was $171.6 million, marking a year-over-year increase of 57.91%. This contributed to the annual value of $188.0 million for FY2025, which is 33.86% up from last year.
  • Per KalVista Pharmaceuticals' latest filing, its Operating Expenses stood at $188.0 million for FY2025, which was up 33.86% from $140.4 million recorded in FY2024.
  • KalVista Pharmaceuticals' Operating Expenses' 5-year high stood at $188.0 million during FY2025, with a 5-year trough of $57.9 million in FY2021.
  • Moreover, its 3-year median value for Operating Expenses was $140.4 million (2024), whereas its average is $146.4 million.
  • Data for KalVista Pharmaceuticals' Operating Expenses shows a peak YoY spiked of 66.80% (in 2022) over the last 5 years.
  • KalVista Pharmaceuticals' Operating Expenses (Yearly) stood at $57.9 million in 2021, then spiked by 66.80% to $96.6 million in 2022, then increased by 14.76% to $110.9 million in 2023, then climbed by 26.67% to $140.4 million in 2024, then skyrocketed by 33.86% to $188.0 million in 2025.